Condition
Acute Exacerbation of Chronic Obstructive Airways Disease
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 3 (1)
P 4 (2)
Trial Status
Completed2
Unknown2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01513655Phase 4Unknown
Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation
NCT01944033Phase 3CompletedPrimary
β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation
NCT02171338Phase 4Unknown
Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections
NCT01291303Not ApplicableCompletedPrimary
Optimization of Ventilator Setting for Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Showing all 4 trials